PRO045, 9.0 mg/kg/week ( DrugBank: - )


1 disease
IDDisease name (Link within this page)Number of trials
113Muscular dystrophy1

113. Muscular dystrophy


Clinical trials : 622 Drugs : 485 - (DrugBank : 99) / Drug target genes : 59 - Drug target pathways : 168
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1NCT01826474
(ClinicalTrials.gov)
January 201320/3/2013Phase IIb Study of PRO045 in Subjects With Duchenne Muscular DystrophyA Phase IIb, Open-label Study to Assess the Efficacy, Safety, Pharmacodynamics and Pharmacokinetics of Multiple Subcutaneous Doses of PRO045 in Subjects With Duchenne Muscular DystrophyDuchenne Muscular DystrophyDrug: PRO045, 0.15 mg/kg/week;Drug: PRO045, 1.0 mg/kg/week;Drug: PRO045, 3.0 mg/kg/week;Drug: PRO045, 6.0 mg/kg/week;Drug: PRO045, 9.0 mg/kg/week;Drug: PRO045, selected doseBioMarin PharmaceuticalNULLTerminated5 Years18 YearsMale15Phase 1/Phase 2Belgium;France;Italy;Netherlands;United Kingdom